hameln pharma ApS: Financial statements 2022
CVR: 39720213
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
hameln pharma ApS (CVR 39720213) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 2,613,040 and a net result of DKK 1,910,112 compared with DKK 1,416,578 the year before. That is an increase of 39.4% compared with the year before. Equity in the 2022 report amounted to DKK 5,043,964. The solvency ratio was 53.5%.
- Gross Profit
- DKK 2,613,040
- Profit/Loss
- DKK 1,910,112
- Equity
- DKK 5,043,964
- Total Assets
- DKK 9,435,261
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | 2.6 mio. | 1.9 mio. | 5 mio. | 0 |
| 2021 | - | 1.9 mio. | 1.4 mio. | 3.2 mio. | 0 |
| 2020 | - | 2.4 mio. | 1.9 mio. | 1.8 mio. | 0 |
Official annual report
Keep an eye on hameln pharma ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Hameln pharma ApS has published its annual report for 2021. Gross profit came to DKK 1,874,153, and the net result was DKK 1,416,578.
About hameln pharma ApS
hameln pharma ApS is a Danish company of the type Anpartsselskab based in Glostrup, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Frank Jahrand and Stephen Allen Watkin. The company is owned by hameln pharma gmbh. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 10,300,176 and a net result of DKK 8,050,599 compared with DKK 5,288,671 the year before. Equity in the 2025 report amounted to DKK 20,334,774.